| A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS (NCT00375284) | Boehringer Ingelheim | 2006-09-01 |
| XP13512 vs. Placebo in Patients With Restless Legs Syndrome. (NCT00365352) | XenoPort, Inc. | 2006-08-01 |
| Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances (NCT00356096) | Boehringer Ingelheim | 2006-07-01 |
| A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS (NCT00349531) | Boehringer Ingelheim | 2006-07-01 |
| The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome (NCT00357097) | GlaxoSmithKline | 2006-06-01 |
| XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. (NCT00333359) | XenoPort, Inc. | 2006-06-01 |
| Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS) (NCT02231918) | Boehringer Ingelheim | 2006-05-01 |
| SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole (NCT00344994) | Augusta University | 2006-05-01 |
| Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS) (NCT02248155) | Boehringer Ingelheim | 2006-04-01 |
| Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome. (NCT00311363) | XenoPort, Inc. | 2006-04-01 |
| REQUIP RLS Post Marketing Surveillance (NCT01327339) | GlaxoSmithKline | 2006-04-01 |
| A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole (NCT00422994) | GlaxoSmithKline | 2006-04-01 |
| XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome. (NCT00298623) | XenoPort, Inc. | 2006-03-01 |
| Long-term Study Of Ropinirole In Restless Legs Syndrome (NCT00329602) | GlaxoSmithKline | 2006-03-01 |
| Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS) (NCT02248142) | Boehringer Ingelheim | 2006-02-01 |
| RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole (NCT00314860) | GlaxoSmithKline | 2006-02-01 |
| An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome (NCT00263068) | UCB Pharma | 2005-12-01 |
| Restless Legs Syndrome Exercise Intervention (NCT00258492) | Northeastern Ohio Universities College of Medicine | 2005-12-01 |
| Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) (NCT00256854) | GlaxoSmithKline | 2005-11-14 |
| Comprehensive Police Fatigue Management Program (NCT00246051) | Brigham and Women's Hospital | 2005-11-01 |
| A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome (NCT00275236) | UCB Pharma | 2005-11-01 |
| Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome (NCT00355641) | GlaxoSmithKline | 2005-10-01 |
| Sequential Compression Devices for Treatment of Restless Legs Syndrome (NCT00479531) | Walter Reed Army Medical Center | 2005-09-01 |
| Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome (NCT00199446) | Kyowa Kirin, Inc. | 2005-07-01 |
| Ropinirole Tablets In Young Patients With Restless Legs Syndrome (NCT00140712) | GlaxoSmithKline | 2005-06-10 |
| Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome (NCT00197080) | GlaxoSmithKline | 2005-06-01 |
| Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome (NCT00135993) | UCB Pharma | 2005-05-01 |
| Sleep Disorders Management, Health and Safety in Police (NCT00207285) | Brigham and Women's Hospital | 2005-05-01 |
| Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome (NCT00136045) | UCB Pharma | 2005-05-01 |
| A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS) (NCT00225862) | GlaxoSmithKline | 2005-01-01 |
| Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome (NCT00152997) | Boehringer Ingelheim | 2004-08-01 |
| Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS) (NCT00133198) | Boehringer Ingelheim | 2004-04-01 |
| A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.) (NCT00152958) | Boehringer Ingelheim | 2004-01-01 |
| Relationship Between Sensory and Motor Systems in Restless Leg Syndrome (NCT00074672) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-12-12 |
| Iron Sucrose In The Treatment of Restless Legs Syndrome: Safety of Three Dose Regimens as Evaluated by Clinical Assessments (NCT00895232) | American Regent, Inc. | 2003-11-01 |
| A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS) (NCT00247364) | Sleep Health Centers | 2003-11-01 |
| A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome (NCT00363857) | GlaxoSmithKline | 2003-08-01 |
| Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS) (NCT00498186) | UCB Pharma | 2003-07-01 |
| Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome (NCT00144209) | Boehringer Ingelheim | 2003-02-01 |
| Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome (NCT00051961) | National Institute of Neurological Disorders and Stroke (NINDS) | 2003-01-14 |
| A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS (NCT00625547) | Pfizer | 2003-01-01 |
| A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS (NCT00627003) | Pfizer | 2002-11-01 |
| Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients (NCT00275457) | Boehringer Ingelheim | 2002-10-01 |
| Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS) (NCT00239486) | Boehringer Ingelheim | 2002-10-01 |
| Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome (NCT00200941) | Neurocare | 2001-08-01 |
| Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) (NCT00367822) | Axxonis Pharma AG | |